Expression of aquaglyceroporins in epithelial ovarian tumours and their clinical significance

Protein levels of aquaglyceroporins AQP3, AQP7 and AQP9 were measured by immunohistochemistry and Western blotting in epithelial ovarian tumour tissue from 98 patients and in normal ovary tissue from 20 persons with uterine myoma. AQP3 and AQP9 proteins were detected immunohistochemically in the basolateral membranes of benign and borderline tumour cells and were found to be distributed throughout the plasma membranes of malignant tumour cells. AQP7 protein was localized in the plasma membranes of benign tumour cells but, in borderline and malignant tumour cells, it was selectively stained in the nuclear membrane. Western blotting showed significantly higher AQP7 and AQP9 protein expression in malignant and borderline tumours than in benign tumour and normal ovarian tissue. AQP9 expression level was positively and significantly correlated with tumour grade and histological type. It was concluded that a high level of aquaglyceroporin expression may be an important factor in ovarian carcinogenesis.     

The correlation between plasma fibrinogen levels and the clinical features of patients with ovarian carcinoma

Pre-operative plasma levels of fibrinogen, plasma prothrombin time, activated partial thromboplastin time and thrombin time (TT) were retrospectively examined in 105 patients with ovarian carcinoma and 21 control patients with benign ovarian tumour. Plasma cancer antigen 125 (CA-125) levels, pathological type, age, body mass index and blood group were evaluated. The TTs of patients with stage III and stage IV ovarian carcinoma were significantly shorter than in controls. Levels of plasma fibrinogen in patients with stage III and IV ovarian carcinoma were higher than those in patients with stage I and II ovarian carcinoma and the controls. There was a positive relationship between levels of plasma CA-125 and plasma fibrinogen in patients with stage II malignancy. There were no significant differences between plasma fibrinogen levels in patients of different age, BMI, blood group and pathological type. Shorter TT was an indication of advanced stage ovarian carcinoma, and fibrinogen was associated with the peritoneal carcinomatosis of ovarian carcinoma.     

结直肠癌患者血清IL-23和IL-10水平的检测及其意义

目的探讨结直肠癌进展过程中,患者血清中几种细胞因子水平的变化及其在肿瘤进程中的意义。方法纳入50例患者及20例健康志愿者,运用ELISA方法检测各组血清IL-23I、L-17I、L-10和IFN-α水平的变化。结果结直肠癌患者血清IL-23和IL-10水平显著高于对照组,而且Ⅳ期患者血清IL-10水平显著高于Ⅰ、Ⅱ、Ⅲ期。结论与IL-17和IFN-α相比,患者血清中IL-23和IL-10表达水平显著增加;此外,患者血清中IL-10的高水平表达可能促进了结直肠癌的发展。     

卵巢上皮性癌中 Livin 蛋白的表达及临床意义

目的 探讨研究 Livin 蛋白在正常卵巢组织、卵巢良性肿瘤组织及卵巢上皮性癌中的表达及与卵巢上皮性癌临床病理特征的关系。方法 随机选取吉林大学中日联谊医院2008年1月-2009年10月间手术切除的组织标本,其中正常卵巢组织20例、卵巢良性上皮性肿瘤组织20例和卵巢上皮性癌组织60例。应用免疫组织化学法对组织进行染色,以检测 Livin 的表达情况。结果 Livin 蛋白在卵巢上皮性癌组织中的表达明显高于在正常卵巢组织和卵巢良性肿瘤组织,Livin 蛋白在卵巢上皮癌高分化组、中分化组及低分化组中表达存在明显统计学差异（χ^2＝8．08,P ＜0．05）,表达强度随着组织病理学分级逐渐升高而增强,但在不同的手术病理分期和组织学类型中的表达无明显差异．结论 Livin 的高表达可能促进卵巢癌的发生发展,其在卵巢上皮性癌中的高表达可能预示着该肿瘤恶性程度高,预后差,易复发。     

卵巢上皮性肿瘤中PTEN和Survivin的表达及意义

[摘 要] 目的: 研究卵巢上皮性肿瘤中PTEN和Survivin的表达。方法: 采用免疫组织化学法用PTEN和Survivin特异性抗体检测PTEN和Survivin在57例卵巢上皮性癌、20例卵巢良性上皮性肿瘤和10例正常卵巢组织标本中的表达。结果: (1) 卵巢上皮性癌中Survivin的阳性表达率（64.91%）明显高于正常卵巢组织中的表达率（0%）及卵巢良性上皮性瘤中的表达率（0%）(Ｐ<0.01), Survivin在卵巢上皮性癌中的过度表达率为52.63%;（2）卵巢上皮性癌中PTEN的阳性表达率（38.60%）明显低于正常卵巢组织的表达率（100%）及卵巢良性上皮性瘤中的表达率（95.00%）(Ｐ<0.05);（3）Survivin的阳性表达、PTEN的阴性表达及Survivin阳性与PTEN阴性的共表达与卵巢上皮性癌的临床分期、病理分级正相关(Ｐ<0.05)。结论:（1）Survivin的表达上调及PTEN的表达下调与卵巢上皮性癌的发生相关,并且在卵巢上皮性癌的发生发展中有协同作用,联合检测其中的指标对于评价卵巢上皮性癌的恶性程度、转移及预后具有临床价值。（2）用PTEN对卵巢上皮性癌进行基因治疗或对卵巢上皮性癌进行针对Survivin的基因治疗及靶向性药物治疗有一定的可能性。     

卵巢癌伴前哨淋巴结转移手术前后IL-6动态变化的临床意义

目的 通过对52例卵巢癌患者手术前、后血清白细胞介素-6 (IL-6)的动态检测,术后根据癌肿病理有、无前哨淋巴结转移情况分组,另将卵巢良性病变病例设为参考对照组进行分类,探讨血清IL-6表达与卵巢良性及恶性肿瘤间的相关性.方法 采用双抗体夹心法(ELISA法)动态检测52例卵巢癌患者及45例卵巢良性病变患者手术前、后的血清IL-6值,并根据术后病理有无前哨淋巴结转移分组,逐组按其手术前、后的血清IL-6表达情况进行相关回顾性分析及对比.结果 ①实验组患者其手术前、后血清IL-6水平明显高于卵巢良性病变组(P<0.01);②回顾性分析中显示有前哨淋巴结转移患者其手术前血清中IL-6水平表达高于无前哨淋巴结转移组(P<0.05).③两组患者术后血清中IL-6水平表达无差异性改变;④实验组患者术后血清中IL-6水平明显下降,手术前、后对比呈显著性差异(P<0.01).结论 卵巢癌患者血清IL-6检测值表达的动态变化与肿瘤是否存在前哨淋巴结转移的发生、发展呈正相关性改变.     

黏附分子和血管内皮生长因子在卵巢上皮性肿瘤中的表达及临床意义

目的研究黏附分子(MUC4)和血管内皮生长因子(VEGF)在卵巢上皮性肿瘤中的表达及临床意义。方法采用免疫组化技术检测20例卵巢良性肿瘤、10例卵巢交界性肿瘤、60例卵巢上皮性卵巢癌组织进行MUC4和VEGF的表达。结果MUC4和VEGF在卵巢良性肿瘤、交界性瘤、上皮性卵巢癌表达差异有显著性(P0.05);MUC4和VEGF在卵巢癌中低分化组织中表达率与高分化组织中相比,差异有显著性(P0.01);在Ⅰ、Ⅱ期(早期)和Ⅲ、Ⅳ期(晚期)卵巢癌组织中,VEGF的表达差异有显著性(P0.01),两组中MUC4的表达差异无显著性;在CA125正常组和CA125升高组中,VEGF的表达差异有显著性(P0.01),两组中MUC4的表达差异无显著性;在早期上皮性卵巢癌中,MUC4表达高于VEGF,差异有显著性(P0.01)。结论MUC4与卵巢肿瘤的良恶性、病理分级有关,与临床分期、CA125值无关,VEGF与卵巢肿瘤的良恶性、临床分期、CA125值、病理分级有关。MUC4是上皮性卵巢癌早期诊断的候选指标,VEGF与预后有关,2者联合检测可提高对上皮性卵巢癌诊断的敏感度,能更好的评估病情及预后。     

MACC1和HGF在卵巢上皮性癌的表达及其与临床病理特征的关系

目的探讨结肠癌转移相关因子1(MACC1)和肝细胞生长因子(HGF)的表达与卵巢恶性上皮性肿瘤临床、病理特征的关系。方法免疫组织化学法和逆转录-聚合酶链反应(RT-PCR)检测47例上皮性卵巢癌、25例良性卵巢上皮性肿瘤、20例正常卵巢上皮性组织中MACC1、HGF蛋白及二者mRNA的表达。结果 (1)卵巢上皮性癌组织中MACC1和HGF蛋白的阳性表达率及相对表达量均显著高于良性上皮性肿瘤和正常卵巢组织(P均<0.05),而在卵巢良性肿瘤组织与正常卵巢组织中的表达差异无统计学意义(P>0.05);(2)卵巢上皮性癌组织中MACC1及HGF蛋白的表达与患者年龄、组织学类型无关(P均>0.05),与临床分期、组织学分级及淋巴结转移有关(P均<0.05);(3)MACC1 mRNA、HGF mRNA在卵巢上皮性癌组织中的表达量显著高于良性卵巢上皮性肿瘤和正常卵巢组织(F=295.032,P=0.00;F=177.252,P=0.00),且卵巢上皮性癌组织中MACC1 mRNA、HGF mRNA的表达水平呈正相关关系(r=0.810,P<0.01)。结论 MACC1可能在卵巢癌的恶性进展中发挥重要作用,有望成为上皮性卵巢癌诊断和治疗的靶点,与HGF联合检测对判断卵巢上皮性肿瘤预后有重要意义。     

Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma

The role of urokinase plasminogen activator receptor (uPAR) and c-erbB-2 in breast and ovarian cancer was investigated. Eighty patients of breast and ovarian cancer and benign lesions, as well as twenty normal controls were evaluated for the expression of c-erbB-2 by Western blotting and uPAR levels by ELISA. The c-erbB-2 and uPAR showed a significant increase in both types of cancer investigated compared to normal control and benign lesions. The frequency of c-erbB-2 was significantly higher in breast cancer lesions (p < 0.01). Levels of CA15.3 in breast cancer and CA125 in ovarian cancer were significantly higher in cases expressing c-erbB-2 (p < 0.01) than in negative c-erbB-2 cases. The uPAR showed a significant positive correlation with advanced stages of breast cancer (r = 0.7971) and ovarian cancer (r = 0.83662), while significant correlations were found for CA15.3 in breast cancer (r = 0.64967) and CA125 in ovarian cancer (r = 0.83996). Taken together, our data suggest that the c-erbB-2 and uPAR in the sera of ovarian and breast cancer act as valuable markers for the evaluation of the patients preoperatively.     

卵巢上皮性癌中Smac蛋白的表达及临床意义

目的：探讨研究Smac蛋白在正常卵巢组织、卵巢良性肿瘤组织及卵巢上皮性癌中的表达及与卵巢上皮性癌临床病理特征的关系。方法随机选取吉林大学中日联谊医院2008年1月-2009年10月间手术切除的卵巢组织标本,其中正常卵巢组织20例、卵巢良性上皮性肿瘤组织20例和卵巢上皮性癌组织60例。应用免疫组织化学法对组织进行染色,以检测Smac的表达情况。结果Smac蛋白在卵巢上皮性癌组织中的表达明显低于正常卵巢组织和卵巢良性肿瘤组织（P＜0．05）,并且Smac蛋白的表达随着组织病理分级的升高而逐渐减弱（P＜0．05）,随着手术病理分期的升高而逐渐减弱（P＜0．05）,但在不同的组织学类型中的表达无明显差异（P＞0．05）。结论Smac的低表达可能促进卵巢癌的发生发展,可能预示着肿瘤更具有侵袭性和不良的预后。     

The role of HE4 in ovarian cancer: inhibiting tumour cell proliferation and metastasis

As a promising biomarker, human epididymis protein 4 (HE4) has been widely used for the early detection and differential diagnosis of ovarian cancer. This study evaluated the function of HE4 in the carcinogenesis and progression of ovarian cancer. An enzyme immunometric assay, used to detect HE4 in the serum of ovarian cancer patients, showed that the protein could discriminate between malignant and benign ovarian tumours with high specificity. An exogenous HE4 gene was transfected into ovarian cancer cell lines and an immortalized ovarian epithelial cell line. Compared with the controls, HE4 overexpression significantly promoted cell apoptosis and adhesion. Overexpression of HE4 also led to significant inhibition of cell proliferation, migration and invasiveness in vitro, as well as xenograft tumour formation in vivo. This is the first report to demonstrate the functional importance of HE4 in multiple cellular processes and indicates that HE4 may play a protective role in the progression of ovarian cancer.     

卵巢癌中Twist和E-cadherin的表达及预后意义

目的 探讨Twist及E-cadherin(E-cad)在卵巢癌中的表达及预后意义.方法 选择具有完整临床病理资料及随访资料结果的卵巢癌50例,同时选取20例良性卵巢囊腺瘤组织和20例卵巢交界性囊腺瘤组织作为对照,采用免疫组织化学SP法分别检测Twist和E-cad的表达情况,分析其表达与临床病理特征及患者预后的关系.结果 Twist在卵巢癌中的表达显著高于良性卵巢囊腺瘤组织和交界性囊腺瘤组织(P<0.001);E-cad在卵巢癌组织中表达显著低于良性及交界性卵巢囊腺瘤组织(P<0.05).Twist和E-cad在卵巢癌中表达呈显著负相关(r=-0.491,P<0.001);卵巢癌组织中Twist的表达与临床FIGO分期、组织学分级、腹水、淋巴结转移相关(P<0.05);Kaplan-Meier生存曲线分析显示患者术后生存率随Twist阳性表达呈现下降趋势,而随E-cad阳性表达显著上升;单因素预后分析提示Twist(P<0.001)、E-cad(P＝0.042)表达异常、FIGO分期(P＝0.001)、组织学分级(P＝0.004)、腹水(P＝0.003)、淋巴结转移(P<0.001)与预后相关.Cox多因素分析提示仅FIGO分期为独立危险因素(P＝0.005).结论 卵巢癌中Twist与E-cad的异常表达与其侵袭转移密切相关,可能在卵巢癌的发生发展中起着重要作用,Twist和E-cad蛋白检测可作为临床上卵巢癌预后判断的参考指标之一.     

原发性卵巢癌组织中肺耐药相关蛋白的表达及其临床价值

目的研究肺耐药相关蛋白(LRP)在原发性卵巢癌组织中的表达状况,探讨其在卵巢癌化学治疗耐药中的作用机制,以及与临床病理生物学特征间的相关性。方法应用免疫组织化学技术对52例原发性卵巢癌、12例卵巢良性肿瘤和10例正常卵巢组织中肺耐药相关蛋白表达状况进行测定。结果肺耐药相关蛋白(LRP)在卵巢癌组织中阳性表达率均显著高于良性肿瘤和正常组织对照组。LRP阳性表达与卵巢癌组织类型、肿瘤分化程度无关,但与临床病理分期及化疗敏感性相关显著,Ⅲ、Ⅳ期组织中LRP阳性表达率显著高于Ⅰ、Ⅱ期。结论LRP在原发性卵巢癌中存在较稳定的表达。检测LRP对前瞻性预测化疗药物敏感性和判断化疗疗效具有一定的临床指导价值。     

内窥镜在诊治化脓性胆管炎中的应用价值

江苏省苏北医院2004年2月成功引经内镜下逆行胰胆管造影术（ERCP）、十二指肠乳头括约肌切开术（EST）、鼻胆管引流术（ENBD）技术以来，对本院收治的9例化脓性胆管炎（ASC）患者试行内镜诊治，达到理想结果，报道如下。     

HuR与环氧化酶-2在卵巢上皮性癌表达及相关性研究

目的 探讨HuR和环氧化酶(COX-2)与卵巢上皮性癌临床病理参数的关系及二者的相关性.方法 收集原发卵巢上皮性癌组织68例(卵巢上皮性癌组),交界性卵巢肿瘤10例(交界性卵巢肿瘤组),正常卵巢组织5例(正常卵巢组织组)行免疫组织化学染色SP法检测HuR与COX-2的表达及与临床病理参数的关系.结果 (1)HuR在卵巢上皮性癌胞核中阳性表达率为76.47%(52/68)明显高于交界性卵巢肿瘤胞核30.00%(3/10)和正常卵巢组织(正常卵巢组织无表达)(x2=18.873,P＜0.05);HuR在交界性卵巢肿瘤的表达与正常卵巢组织比较差异无统计学意义(P＞0.05).(2)HuR在卵巢上皮性癌和交界性卵巢肿瘤胞质中的阳性表达率分别为45.60%(31/68)、10.00%(1/10),正常卵巢组织无表达;胞质HuR在恶性卵巢肿瘤组织的表达与交界性卵巢肿瘤和正常卵巢组织比较差异有统计学意义(x2=7.999,P=0.018);胞质HuR在交界性卵巢肿瘤的表达与正常卵巢组织比较差异无统计学意义(P＞0.05).(3)临床分期Ⅲ、Ⅳ期胞质HuR的阳性表达率为56.09%(23/41),显著高于Ⅰ、Ⅱ期的29.63%(8/27),差异有统计学意义(x2=4.598,P=0.032).在组织学分级高分化、中分化、低分化胞质HuR的阳性表达率分别为10.00%(1/10)、46.67%(14/30)、57.14%(16/28),差异有统计学意义(x2=6.627,P=0.036).(4)COX-2在卵巢上皮性癌(67.64%)和交界性卵巢肿瘤(60.00%)的表达明显高于正常卵巢组织(0),在卵巢上皮性癌的表达与交界性卵巢肿瘤比较差异无统计学意义(P＞0.05);COX-2高表达与临床分期和淋巴结转移有关;(5)胞质HuR与COX-2在肿瘤中的表达呈正相关(x2=0.317,P=0.008).结论 HuR与COX-2在卵巢上皮性癌的表达明显增高,且胞质HuR的表达与COX-2的表达呈正相关,提示胞质HuR与COX-2的过表达可能与卵巢癌的发生发展密切相关.

Abstract：

Objective To detect the expressions of HuR and COX-2 in epithelial ovarian carcinoma,and investigate the correlation of HuR and COX-2 expression. In addition, we attempt to seek the pathway to prevent the occurrence and development of epithelial ovarian cancer by combined analysis of various clinicopathologic characteristics. Methods The expressions of HuR and COX-2 in 68 epithelial ovarian carcinoma, 10 borderline ovarian tumors and 5 normal ovarian tissues were examined by S-P immunohistochemical method. The relationship of HuR and COX-2 expressions with clinicopathologic parameterwere evaluated by correlation analysis. Results(1) The expression of HuR in epithelial ovarian cancer tissue (76. 47% ,52/68) was significantly higher than that in borderline epithelial ovarian tumor tissues (30. 00% ,3/10) and normal ovarian tissues (0, x2 = 18. 873, Ps ＜ 0. 05), but there were no significant differences betweenthe expressions of HuR in borderline epithelial ovarian tumor and normal ovarian tissue(P ＞ 0. 05).(2) The positive expression rate of cytoplasmic HuR in epithelial ovarian carcinoma and borderline epithelial ovarian tumor were 45.60% (31/68) and 10. 00% (1/10) respectively,but normal ovarian tissues showed no staining of HuR. We found no significant differences between the expression of cytoplasmic HuR in epithelial ovarian carcinoma and borderline epithelial ovarian tumor or normal ovarian tissue(x2 = 7. 999 ,P =0. 018).(3) The positive expression rate of cytoplasmic HuR in epithelial ovarian carcinoma of FIGO stage Ⅲ - Ⅳ was significantly higher than that of stage Ⅰ - Ⅱ(56. 09% vs. 29. 63%, x2 = 4. 598, P = 0. 032). The positive expression rates of cytoplasmic HuR in epithelial ovarian carcinoma of histological grade 1,2,3 were 10. 00%,46. 67% ,57. 14% respectively, which showed significant difference in the comparison among the three groups (x2 =6. 627 ,P =0. 036). (4) The positive expression rates of COX-2 in epithelial ovarian cancer (67. 64%)and borderline epithelial ovarian tumor tissues (60. 00%) were significantly higher than that in normal ovarian tissues (0, Ps ＜ 0. 05), but we found no significant difference in the comparison between the expression of malignant and borderline ovarian tumors. Statistical analysis showed that the positive expression rate of COX-2 in epithelial ovarian carcinoma was correlated with FIGO stage and lymph node metastasis. (5)There was a significantly positive correlation between cytoplasmic HuR and COX-2 expressions in epithelial ovarian carcinoma. Conclusion The expressions of HuR and COX-2 increased in the epithelial ovarian carcinoma, and the cytoplasmic expression of HuR was significantly correlated with the expression of COX-2. These results suggested that increased cytoplasmic expression of HuR and COX-2 expression might play important roles in the initiation and development of epithelial ovarian carcinoma.     

VEGF—C和TSP-1在卵巢上皮癌中的表达及意义

目的检测人卵巢上皮癌组织中血管内皮生长因子C（VEGF—C）、凝血酶敏感蛋白1（TSP-1）表达及微血管密度（MVD），探讨VEGF—C、TSP-1与卵巢癌临床病理特征之间的关系。方法以免疫组化法检测卵巢上皮癌50例以及正常卵巢组织20例石蜡标本中VEGF—C、TSP—1表达及MVD。结果卵巢上皮癌中VEGF—C表达及MVD均明显高于正常卵巢组织（P〈0．05），TSP-1表达低于正常卵巢组织（P〈0．05）；卵巢上皮癌组织中，VEGF—C表达及MVD随国际妇产科联盟（FIGO）分期的进展而增高（P〈0．05），TSP-1表达随FIGO分期的进展而降低（P〈0．05）。结论卵巢上皮癌组织中VEGF—C过表达及TSP-1低表达与肿瘤血管生成及侵袭进展密切相关。     

肺癌中细胞黏附分子-1和L-选择素的表达及临床意义

目的：检测细胞黏附分子-1（ICAM-1）和L-选择素水平，探讨其与肺癌发展、转移、治疗、预后之间的关系。方法：采用免疫组织化学法检测48例肺癌组织ICAM-1的表达，用酶联免疫吸附试验检测48例肺癌患者、18例肺良性病变患者及20例健康志愿者血ICAM-1和L-选择素的浓度。结果：（1）Ⅲ＋IV期肺癌组织和有淋巴结转移者ICAM-1表达分别显著高于Ⅰ＋Ⅱ期和无淋巴结转移者，腺癌组织中ICAM-1表达显著高于鳞癌。（2）肺癌和肺良性病变患者血中ICAM-1和L-选择素水平明显高于健康志愿者，肺癌与肺良性病变患者ICAM-1相比差异有显著性，而L-选择素差异无显著性。Ⅲ＋Ⅳ期显著高于Ⅰ＋Ⅱ期，有转移者与无转移者相比差异均有统计学意义。结论：组织ICAM-1与肺癌的发展和转移有关．检测血ICAM-1和L-选择素含量可以作为肺癌术前诊断及术后效果评估指标之-。     

骨桥蛋白在卵巢上皮癌组织中的表达及其与预后的关系

目的 探讨卵巢上皮癌组织中骨桥蛋白的表达及其与预后的关系.方法 应用免疫组织化学法测定骨桥蛋白在64例卵巢上皮癌组织、20例卵巢良性肿瘤组织及10例卵巢正常组织中的表达,分析其表达与临床病理分期及其与预后的关系.结果 64例卵巢上皮癌患者组织中骨桥蛋白表达阳性52例,骨桥蛋白在卵巢上皮癌组织中的阳性表达率[81.3%(52/64)明显高于卵巢良性肿瘤[15.0%(3/20)]及正常卵巢组织[10.0%(1/10)],差异有统计学意义(P均<0.01).骨桥蛋白的表达与卵巢上皮癌的分期、分化及有无腹水和淋巴结转移有关.骨桥蛋白阴性表达组患者的总生存时间(2年生存率为91.7%,3年生存率为83.3%)明显高于骨桥蛋白阳性表达组(2年为67.3%,3年为55.6%).结论 骨桥蛋白与卵巢上皮癌的发生、发展及其预后密切相关.     

卵巢上皮性癌中P-选择素的表达及临床意义

目的探讨研究P-选择素在正常卵巢组织、卵巢良性肿瘤组织、卵巢交界性上皮性肿瘤及卵巢上皮性癌中的表达及与卵巢上皮性癌临床病理特征的关系。方法随机选取吉林大学中日联谊医院和长春市中心医院2008年1月-2009年10月间手术切除的组织标本,其中正常卵巢组织20例、卵巢良性上皮性肿瘤组织20例、卵巢交界性上皮性肿瘤18例和卵巢上皮性癌组织60例。应用免疫组织化学法对组织进行染色,以检测P-选择素的表达情况。结果 （1）P-选择素在不同性质的卵巢组织的细胞膜或细胞浆中均有表达,主要表达于细胞膜中,正常卵巢组织、良性上皮性肿瘤、交界性上皮性肿瘤、上皮性癌中的阳性表达率依次为10.0%、20.0%、27.8%、63.3%,整体之间的阳性表达率比较,差异有显著性。（2）P-选择素在卵巢上皮性癌中的表达随着手术-病理分期和组织病理学分级的升高而增加,而与肿瘤组织学类型无关。结论 （1）P-选择素可能参与卵巢上皮性癌的发生发展,在卵巢恶性肿瘤的发展中起着重要的作用;（2）P-选择素高表达促进了肿瘤的侵袭和转移,表达越高,恶性程度越高、预后越差、越易复发。